Galectin-1 Is a Novel Functional Receptor for Tissue Plasminogen Activator in Pancreatic Cancer

Gastroenterology

Volumn 136, Issue 4, 2009, Pages

  Roda, Oriol ^a,b   Ortiz Zapater, Elena ^a,b   Martínez Bosch, Neus ^a   Gutiérrez Gallego, Ricardo ^a,b   Vila Perelló, Miquel ^b   Ampurdanés, Coral ^a   Gabius, Hans Joachim ^c   André, Sabine ^c   Andreu, David ^b   Real, Francisco X ^a,b,d   Navarro, Pilar ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITY OF MUNICH   (Germany)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CANCER GROWTH; CATALYSIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; STROMA; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

EID: 63149170012     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.12.039     Document Type: Article

References (39)

1. Carmeliet P., Schoonjans L., Kieckens L., et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368 (1994) 419-424
2. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 82 (1999) 259-270
3. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 86 (2001) 138-143
4. Nicole O., Docagne F., Ali C., et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7 (2001) 59-64
5. Medina M.G., Ledesma M.D., Dominguez J.E., et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 24 (2005) 1706-1716
6. Hu K., Yang J., Tanaka S., et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 281 (2006) 2120-2127
7. Siao C.J., and Tsirka S.E. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 22 (2002) 3352-3358
8. Diaz V.M., Hurtado M., Thomson T.M., et al. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 53 (2004) 993-1000
9. Ortiz-Zapater E., Peiro S., Roda O., et al. Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. Am J Pathol 170 (2007) 1573-1584
10. Hernández-Muñoz I., Skoudy A., Real F.X., et al. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8 (2008) 462-469
11. Paciucci R., Tora M., Diaz V.M., et al. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 16 (1998) 625-633
12. Aguilar S., Corominas J.M., Malats N., et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 165 (2003) 1129-1139
13. Missiaglia E., Blaveri E., Terris B., et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer 112 (2004) 100-112
14. Ryu B., Jones J., Blades N.J., et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 62 (2002) 819-826
15. Diaz V.M., Planaguma J., Thomson T.M., et al. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 122 (2002) 806-819
16. Roda O., Chiva C., Espuna G., et al. A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells. Proteomics 6 (2006) S36-S41
17. Perillo N.L., Marcus M.E., and Baum L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76 (1998) 402-412
18. Danguy A., Camby I., and Kiss R. Galectins and cancer. Biochim Biophys Acta 1572 (2002) 285-293
19. Liu F.T., and Rabinovich G.A. Galectins as modulators of tumour progression. Nat Rev Cancer 5 (2005) 29-41
20. Villalobo A., Nogales-González A., and Gabius H.J. A guide to signaling pathways connecting protein-glycan interaction with the emerging versatile effector functionality of mammalian lectins. Trends Glycosci Glycotechnol 18 (2006) 1-37
21. Berberat P.O., Friess H., Wang L., et al. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49 (2001) 539-549
22. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63 (2003) 8614-8622
23. Shen J., Person M.D., Zhu J., et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64 (2004) 9018-9026
24. Chen R., Yi E.C., Donohoe S., et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129 (2005) 1187-1197
25. Gutiérrez G.R., Haseley S.R., van Miegem V.F., et al. Identification of carbohydrates binding to lectins by using surface plasmon resonance in combination with HPLC profiling. Glycobiology 14 (2004) 373-386
26. Andre S., Kaltner H., Furuike T., et al. Persubstituted cyclodextrin-based glycoclusters as inhibitors of protein-carbohydrate recognition using purified plant and mammalian lectins and wild-type and lectin-gene-transfected tumor cells as targets. Bioconjug Chem 15 (2004) 87-98
27. Lopez-Lucendo M.F., Solis D., Andre S., et al. Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol 343 (2004) 957-970
28. Mueller M.M., and Fusenig N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4 (2004) 839-849
29. Rabinovich G.A. Galectin-1 as a potential cancer target. Br J Cancer 92 (2005) 1188-1192
30. Camby I., Le Mercier M., Lefranc F., et al. Galectin-1: a small protein with major functions. Glycobiology 16 (2006) 137R-157R
31. Liu D., Aguirre G.J., Estrada Y., et al. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 (2002) 445-457
32. Ono M., and Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J 20 (2004) 71-78
33. Andre S., Sanchez-Ruderisch H., Nakagawa H., et al. Tumor suppressor p16INK4a-modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS J 274 (2007) 3233-3256
34. Moore P.S., Sipos B., Orlandini S., et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439 (2001) 798-802
35. Andre S., Maljaars C.E., Halkes K.M., et al. Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett 17 (2007) 793-798
36. Elad-Sfadia G., Haklai R., Ballan E., et al. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 277 (2002) 37169-37175
37. Fredriksson L., Li H., Fieber C., et al. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23 (2004) 3793-3802
38. Hede K. Environmental protection: studies highlight importance of tumor microenvironment. J Natl Cancer Inst 96 (2004) 1120-1121
39. Sausville E.A. The challenge of pathway and environment-mediated drug resistance. Cancer Metastasis Rev 20 (2001) 117-122